FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wojciech Krzyzanski

Research Profile

Concepts & Ideas

Chemicals & Drugs

Physiology

Anatomy

Reticulocytes

Activities & Behaviors

Computer Simulation

Living Beings

Procedures

Co-author Network

Publications

TOP 3
Xiaoyu Yan; Sihem Ait-Oudhia; Wojciech Krzyzanski
Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness.
Wojciech Krzyzanski; Juan Jose Perez-Ruixo; Bethlyn Sloey; Liviawati Sutjandra; Andrew T Chow; Yow-Ming Wang
Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals.
Xiaoyu Yan; Philip J Lowe; Sigrid Balser; Alexander Berghout; Martin Fink; Wojciech Krzyzanski
Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wojciech Krzyzanski (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Xiaoyu Yan; Sihem Ait-Oudhia; Wojciech Krzyzanski
Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness.
Pharmaceutical research 2013;30(4):1026-36.
2013: Wojciech Krzyzanski; Juan Jose Perez-Ruixo; Bethlyn Sloey; Liviawati Sutjandra; Andrew T Chow; Yow-Ming Wang
Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals.
Pharmaceutical research 2013;30(3):655-69.
2012: Xiaoyu Yan; Philip J Lowe; Sigrid Balser; Alexander Berghout; Martin Fink; Wojciech Krzyzanski
Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.
Journal of clinical pharmacology 2012;52(11):1624-44.
2012: Xiaoyu Yan; Yang Chen; Wojciech Krzyzanski
Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.
Journal of pharmacokinetics and pharmacodynamics 2012;39(5):543-60.
2012: Xiaoyu Yan; Wojciech Krzyzanski
Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model.
Journal of pharmacokinetics and pharmacodynamics 2012;39(2):141-6.
2012: Wojciech Krzyzanski; Juan Jose Perez-Ruixo
Lifespan based indirect response models.
Journal of pharmacokinetics and pharmacodynamics 2012;39(1):109-23.
2011: Melanie A Felmlee; Wojciech Krzyzanski; Bridget L Morse; Marilyn E Morris
Use of a local sensitivity analysis to inform study design based on a mechanistic toxicokinetic model for γ-hydroxybutyric acid.
The AAPS journal 2011;13(2):240-54.
2011: Wojciech Krzyzanski
Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models.
Journal of pharmacokinetics and pharmacodynamics 2011;38(2):179-204.
2011: Sihem Ait-Oudhia; An Vermeulen; Wojciech Krzyzanski
Non-linear mixed effect modeling of the time-variant disposition of erythropoietin in anemic cancer patients.
Biopharmaceutics & drug disposition 2011;32(1):1-15.
2010: Yow-Ming C Wang; Wojciech Krzyzanski; Sameer Doshi; Jim J Xiao; Juan Jose Pérez-Ruixo; Andrew T Chow
Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.
The AAPS journal 2010;12(4):729-40.
2010: Jim J Xiao; Wojciech Krzyzanski; Yow-Ming Wang; Hongyan Li; Mark J Rose; Mark Ma; Yuling Wu; Beth Hinkle; Juan Jose Perez-Ruixo
Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys.
The AAPS journal 2010;12(4):646-57.
2010: Wojciech Krzyzanski; Pawel Wiczling; Phil Lowe; Etienne Pigeolet; Martin Fink; Alexander Berghout; Sigrid Balser
Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.
Journal of clinical pharmacology 2010;50(9 Suppl):101S-112S.
2010: Sihem Ait-Oudhia; Jean-Michel Scherrmann; Wojciech Krzyzanski
Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.
The Journal of pharmacology and experimental therapeutics 2010;334(3):897-910.
2010: Sihem Ait-Oudhia; Jean-Michel Scherrmann; Wojciech Krzyzanski
Time-dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats.
Biopharmaceutics & drug disposition 2010;31(5-6):298-315.
2010: Xiaoyu Yan; Donald E Mager; Wojciech Krzyzanski
Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
Journal of pharmacokinetics and pharmacodynamics 2010;37(1):25-47.
2009: Leonid A Khinkis; Wojciech Krzyzanski; William J Jusko; William R Greco
D-optimal designs for parameter estimation for indirect pharmacodynamic response models.
Journal of pharmacokinetics and pharmacodynamics 2009;36(6):523-39.
2009: Pawel Wiczling; Sihem Ait-Oudhia; Wojciech Krzyzanski
Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2009;75(7):584-92.
2009: Anshu Marathe; Wojciech Krzyzanski; Donald E Mager
Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.
Journal of pharmacokinetics and pharmacodynamics 2009;36(3):199-219.
2009: Pawel Wiczling; Philip Lowe; Etienne Pigeolet; Frank Lüdicke; Sigrid Balser; Wojciech Krzyzanski
Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations.
Clinical pharmacokinetics 2009;48(12):817-26.
2009: Juan José Pérez-Ruixo; Wojciech Krzyzanski; Esther Bouman-Thio; Bruce Miller; Haishan Jang; Stephen A Bai; Honghui Zhou; Jennifer Yohrling; Adam Cohen; Jacobus Burggraaf; Kari Franson; Hugh M Davis
Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects.
Clinical pharmacokinetics 2009;48(9):601-13.
2008: Wojciech Krzyzanski; Juan Jose Perez-Ruixo; An Vermeulen
Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.
Journal of pharmacokinetics and pharmacodynamics 2008;35(3):349-77.
2008: Wojciech Krzyzanski; Elzbieta Wyska
Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers.
Naunyn-Schmiedeberg's archives of pharmacology 2008;377(4-6):637-45.
2008: Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Pharmacodynamic model for chemotherapy-induced anemia in rats.
Cancer chemotherapy and pharmacology 2008;62(1):123-33.
2008: Pawel Wiczling; Wojciech Krzyzanski
Flow cytometric assessment of homeostatic aging of reticulocytes in rats.
Experimental hematology 2008;36(2):119-27.
2008: Juan José Pérez-Ruixo; Wojciech Krzyzanski; Jeremy Hing
Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects.
Clinical pharmacokinetics 2008;47(6):399-415.
2008: Sukyung Woo; Wojciech Krzyzanski; Anne-Marie Duliege; Richard B Stead; William J Jusko
Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers.
Journal of clinical pharmacology 2008;48(1):43-52.
2007: Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).
Journal of pharmacokinetics and pharmacodynamics 2007;34(6):849-68.
2007: Wojciech Krzyzanski; Jonathan Bell
Modelling the geometric features and investigating electrical properties of dendrites in a fish thalamic neuron.
Mathematical medicine and biology : a journal of the IMA 2007;24(3):271-86.
2007: Wojciech Krzyzanski; Jan Oberdoester; Richard A Rabin
Mechanism of ethanol enhancement of apoptosis and caspase activation in serum-deprived PC12 cells.
Life sciences 2007;81(9):756-64.
2007: Pawel Wiczling; Wojciech Krzyzanski
Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2007;71(7):460-7.
2007: Robert M Straubinger; Wojciech Krzyzanski; Crystal M Francoforte; jun qu
Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development.
Anticancer research 2007;27(3A):1237-46.
2007: Wojciech Krzyzanski; Juan Jose Perez-Ruixo
An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects.
Pharmaceutical research 2007;24(4):758-72.
2007: Anson K Abraham; Wojciech Krzyzanski; Donald E Mager
Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition.
The AAPS journal 2007;9(2):E181-9.
2006: Anasuya Hazra; Wojciech Krzyzanski; William J Jusko
Mathematical assessment of properties of precursor-dependent indirect pharmacodynamic response models.
Journal of pharmacokinetics and pharmacodynamics 2006;33(6):683-717.
2006: Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.
The Journal of pharmacology and experimental therapeutics 2006;319(3):1297-306.
2006: Wojciech Krzyzanski; Jacek Dmochowski; Nobuko Matsushima; William J Jusko
Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.
Journal of pharmacokinetics and pharmacodynamics 2006;33(5):635-55.
2006: Wojciech Krzyzanski; Sukyung Woo; William J Jusko
Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.
Journal of pharmacokinetics and pharmacodynamics 2006;33(2):125-66.
2006: Zhenling Yao; Wojciech Krzyzanski; William J Jusko
Assessment of basic indirect pharmacodynamic response models with physiological limits.
Journal of pharmacokinetics and pharmacodynamics 2006;33(2):167-93.
2006: Elzbieta Nowakowska; Krzysztof Kus; Wojciech Krzyzanski; Anna Czubak
Influence of haloperidol and clozapine on some behavioral effects in rats.
Arzneimittel-Forschung 2006;56(12):807-13.
2005: Juan Jose Perez-Ruixo; Hui C Kimko; Andrew T Chow; Vladimir Piotrovsky; Wojciech Krzyzanski; William J Jusko
Population cell life span models for effects of drugs following indirect mechanisms of action.
Journal of pharmacokinetics and pharmacodynamics 2005;32(5-6):767-93.
2005: Wojciech Krzyzanski; William J Jusko; Mary C Wacholtz; Neil Minton; Wing K Cheung
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2005;26(3-4):295-306.
2005: Donald E Mager; Wojciech Krzyzanski
Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.
Pharmaceutical research 2005;22(10):1589-96.
2004: Justin Earp; Wojciech Krzyzanski; Abhijit Chakraborty; Miren K Zamacona; William J Jusko
Assessment of drug interactions relevant to pharmacodynamic indirect response models.
Journal of pharmacokinetics and pharmacodynamics 2004;31(5):345-80.
2004: Feng Jin; Wojciech Krzyzanski
Pharmacokinetic model of target-mediated disposition of thrombopoietin.
AAPS pharmSci 2004;6(1):E9.
2004: Feng Jin; Wojciech Krzyzanski
Pharmacokinetic model of target-mediated disposition of thrombopoietin.
The AAPS journal 2004;6(1):86-93.
2003: Elzbieta Wyska; Donald E Mager; Wojciech Krzyzanski
Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data.
Journal of pharmaceutical sciences 2003;92(7):1438-54.
2002: Wojciech Krzyzanski; Jonathan Bell; Roman R Poznanski
Neuronal integrative analysis of the "Dumbbell" model for passive neurons.
Journal of integrative neuroscience 2002;1(2):217-39.
2002: Itay Perlstein; David Stepensky; Wojciech Krzyzanski; Amnon Hoffman
A signal transduction pharmacodynamic model of the kinetics of the parasympathomimetic activity of low-dose scopolamine and atropine in rats.
Journal of pharmaceutical sciences 2002;91(12):2500-10.
2002: Wojciech Krzyzanski; William J Jusko
Multiple-pool cell lifespan model of hematologic effects of anticancer agents.
Journal of pharmacokinetics and pharmacodynamics 2002;29(4):311-37.
2002: Steven H Bernstein; William J Jusko; Wojciech Krzyzanski; Janet Nichol; Meir Wetzler
Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy.
Journal of clinical pharmacology 2002;42(5):501-11.
2001: T A Puchalski; Wojciech Krzyzanski; RA Blum; William J Jusko
Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model.
Journal of clinical pharmacology 2001;41(3):251-8.
2000: Wojciech Krzyzanski
Asymptotics of the total net direct pharmacological effect for large drug doses.
Journal of mathematical biology 2000;41(6):477-92.
2000: Wojciech Krzyzanski; A Chakraborty; William J Jusko
Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models.
Chronobiology international 2000;17(1):77-93.
1999: Wojciech Krzyzanski; Rohini Ramakrishnan; William J Jusko
Basic pharmacodynamic models for agents that alter production of natural cells.
Journal of pharmacokinetics and biopharmaceutics 1999;27(5):467-89.
1999: Wojciech Krzyzanski; J Bell
Analysis of a model of membrane potential for a skin receptor.
Mathematical biosciences 1999;158(1):1-45.
1999: A Chakraborty; Wojciech Krzyzanski; William J Jusko
Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods.
Journal of pharmacokinetics and biopharmaceutics 1999;27(1):23-43.
1998: Wojciech Krzyzanski; William J Jusko
Note: caution in use of empirical equations for pharmacodynamic indirect response models.
Journal of pharmacokinetics and biopharmaceutics 1998;26(6):735-41.
1998: Wojciech Krzyzanski; William J Jusko
Characterization of pharmacodynamic recession slopes for direct and indirect response models.
Journal of pharmacokinetics and biopharmaceutics 1998;26(4):409-36.
1998: Wojciech Krzyzanski; William J Jusko
Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions.
Journal of pharmacokinetics and biopharmaceutics 1998;26(4):385-408.
1998: Wojciech Krzyzanski; William J Jusko
Integrated functions for four basic models of indirect pharmacodynamic response.
Journal of pharmaceutical sciences 1998;87(1):67-72.
1997: Wojciech Krzyzanski; William J Jusko
Application of moment analysis to the sigmoid effect model for drug administered intravenously.
Pharmaceutical research 1997;14(7):949-52.
1997: Wojciech Krzyzanski; William J Jusko
Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses.
Journal of pharmacokinetics and biopharmaceutics 1997;25(1):107-23.